|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
 |
|||
Latest News: ... Latest Story Further Information: UMIP - Case Studies of Spin-outs
UPF Masterclasses: NOVEMBER 25th 2008 ... More information |
24/10/08 UPF investee Myconostica hires new CEO as it prepares to launch products 18/09/08 UPF makes investment in water treatment company, Arvia Technology 29/07/08 MTI, in its capacity as fund manager of the UPF, shortlisted for the category "Fund Raising of the Year" at the British Private Equity Awards 2008 02/06/08 Darling meets spin-outs during Manchester visit. 01/06/08 22/05/08 The UPF makes its first investment - £1m into molecular diagnostics company Myconostica Limited 21/05/08 Change of management structure and new appointment at MTI 17/04/08 Launch of UPF in Manchester - excerpt from UNILIFE - The magazine of the University of Manchester 17/04/08 BBC Radio Manchester - Interview with Clive Rowland (UMIP) and Torsten Schanze (Nanoco Technologies) 03/04/08 MTI and The University of Manchester announce the first close of the Download PDF (45k) 03/04/08 Real Deals - "Out from the Wilderness" Download PDF (450k)
|
MTI Partners, the technology venture capital investor, and The University of Manchester today announce the first investment from their recently launched UMIP Premier Fund (‘UPF’). UPF was established in April 2008 to invest in University of Manchester spin out companies. With funding from a broad range of UK and European institutional and supranational investors, including EIF (European Investment Fund), the Fund has initial backing of €42 million (£32 million). UPF has invested £1m into Myconostica Ltd - a Manchester UK-based medical diagnostics company which specialises in rapid and highly specific tests for life-threatening fungal infections. Myconostica’s tests detect the two most common causes of fungal pneumonia, which account for over 95% of cases, in less than 4 hours. Fungal pneumonia is the leading cause of infectious death in leukaemia and after bone marrow transplantation and is the most common first manifestation of AIDS.
|
|
|
|
|
|
 |
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
|